Portugal – Antineoplastic and immunomodulating agents – 2023/0491- GOLIMUMAB [50 MG/0.5 ML; SOL INJ; CANETA/SERINGA]
Tender Description
GOLIMUMAB [50 MG/0.5 ML; SOL INJ; CANETA/SERINGA]
Unlock Full Tender Insight
Complete details, deadlines, and AI-powered analysis are available inside the tend.ee platform. Create your free account to access.
It's free to get started. No credit card required.
